Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,732 people get BAX articles and Market Currents by email alert.
Get email alerts on BAX »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
Why We Like Baxter's DividendValuentum • Thu, Oct 25, 2012 -
-
-
-
Baxter Still Defensive, But Is Now The Time For Offense?Stephen Simpson • Tue, May 15, 2012 -
Baxter Earnings PreviewZacks Investment Research • Tue, Apr 17, 2012 -
-
Baxter's A Buy For Growth, Cash Flow, And Rising DividendsIngrid Hendershot • Tue, Mar 13, 2012 -
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
Daily Equity Brief: Bull Signals And SentimentJon Haghayeghi • Wed, May 22 -
-
-
-
-
-
-
-
-
-
-
-
-
-
CareFusion On The Right PathStephen Simpson • Wed, Apr 3
-
Baxter International Inc. - Special CallTue, May 7
-
Baxter International Q2 2010 Earnings Call TranscriptThu, Jul 22, 2010
-
Baxter International Inc. Q1 2010 Earnings Call TranscriptThu, Apr 22, 2010
-
Baxter International Inc. Q4 2009 Earnings Call TranscriptThu, Jan 28, 2010
-
Business Wire (May 23, 2013)
-
Business Wire (May 21, 2013)
-
Business Wire (May 20, 2013)
-
at CNBC.com (May 17, 2013)
-
at CNBC.com (May 7, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 18, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 8, 2013)
-
Business Wire (Mar 27, 2013)
-
Business Wire (Feb 27, 2013)
BAX vs. ETF Alternatives
Company Description
Baxter develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, July 18, 2012, 5:30 PM Notable earnings before Thursday’s open: ADS, BAX, BBT, BX, CY, DGX, DHR, DO, FCS, FCX, FITB, GPC, HBAN, JCI, KEY, LUV, MS, NOK, NUE, NVS, PM, SHW, SWY, TCB, TRV, TSM, TXT, UNH, UNP, VZ Comment! [Earnings]
- Tuesday, July 17, 2012, 12:05 PM AAIC 2012: Baxter's (BAX +1%) Gammagard immune system therapy for Alzheimer's disease performed well in Phase 2 trials, with 4 patients who received the most effective dose experiencing a stabilization over 3 years. It's all very small scale, and the proof will come early next year with the results of a larger Phase 3 study, but it's still really encouraging. Comment! [Healthcare, Quick Ideas]
- Tuesday, June 19, 2012, 8:06 AM Shares of Baxter International (BAX) gain 1.1% premarket after Goldman Sachs adds the company to its Conviction Buy List on a valuation call and with the potential of its pipeline and another dividend increase looming for H2. Comment! [On the Move, Consumer]
- Friday, May 25, 2012, 3:54 PM Baxter International (BAX -0.5%) says the results from two large, international multicenter trials it conducted show that a low glucose peritoneal dialysis regimen favorably impacted metabolic measures important for end-stage renal disease patients with diabetes, including blood glucose control and selected lipids. The combined results were presented at the 49th Annual European Renal Association - European Dialysis and Transplant Association congress in Paris. Comment! [Healthcare]
- Monday, April 30, 2012, 11:08 AM Biogen (BIIB +0.7%) moves up after Deutsche Bank says it conducted a survey and found that 40% - 57% of patients taking Baxter's (BAX +0.1%) Advate would consider switching to BIIB's new hemophilia treatment if the price was right. Comment! [Healthcare]
- Thursday, April 19, 2012, 7:21 AM Baxter International (BAX): Q1 EPS of $0.61 beats by $0.03. Revenue of $3.4B (+14.7% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
- Thursday, April 19, 2012, 12:05 AM Notable earnings before Thursday's open: ADS, BAC, BAX, BBT, BSX, BTU, BX, CY, DD, DHR, DO, EMC, FCS, FCX, FHN, FITB, FNFG, GNTX, KEY, LUV, MS, NOK, NUE, PBCT, PM, PPG, SHW, SWFT, TCB, TRV, UNH, UNP, VZ Comment! [Earnings]
- Wednesday, April 18, 2012, 5:30 PM Notable earnings before Thursday's open: ADS, BAC, BAX, BBT, BSX, BTU, BX, CY, DD, DHR, DO, EMC, FCS, FCX, FHN, FITB, FNFG, GNTX, KEY, LUV, MS, NOK, NUE, PBCT, PM, PPG, SHW, SWFT, TCB, TRV, UNH, UNP, VZ 3 Comments [Earnings]
- Monday, April 16, 2012, 9:22 AM Baxter International (BAX) trades 3.8% lower premarket after it discloses along with partner Halozyme Therapeutics that the FDA needs more long-term data on their jointly-developed HyQ product. Comment! [Healthcare, On the Move]
-
Monday, April 16, 2012, 9:05 AM
Premarket gainers: ECYT +114%. DRJ +30%. CSIQ +9%. SQNM +9%. LDK +7%. TSL +6%. RENN +4%. YGE +4%. STX +4%. JASO +4%. STP +4%. ANR +3%.
Losers: PCO -47%. HALO -22%. SANG -5%. BAX -4%. MAT -4%. RBS -3%. VALE -3%. Comment! [On the Move] - Friday, February 3, 2012, 7:51 AM A new government report shines a bright spotlight on the pricing of high-priced medical devices with cost variance ranging as much as 50% across different hospitals for the purchases of the same products. The GAO report raises "serious concerns" over the prices hospitals and Medicare pay for medical devices, as well as stoking up Congressional backlash on the issue. Companies that could be impacted by pricing reform include MDT, BAX, COV, SYK, TMO, ISRG, BDX, STJ, EW, BSX, BCR, VAR. 1 Comment [Healthcare, Quick Ideas]
- Thursday, January 26, 2012, 7:12 AM Baxter International (BAX): Q4 EPS of $1.17 in-line. Revenue of $3.59B (+2.6% Y/Y) beats by $10M. (PR) Comment! [Earnings, Healthcare]
- Thursday, January 26, 2012, 12:05 AM Notable earnings before Thursday's open: ABC, AME, AN, ARG, AVT, BAX, BC, BLL, BMY, CAT, CELG, CL, CNX, COV, CP, CY, EQT, ESI, ETN, FNFG, IVZ, JBLU, JNS, KMT, LMT, MJN, MKC, MMM, MWW, NOK, NUE, ORI, PCP, POT, RTN, SHW, T, TWC, UA, UAL, VLY, [[ZMH] Comment! [Earnings]
- Wednesday, January 25, 2012, 5:30 PM Notable earnings before Thursday's open: ABC, AME, AN, ARG, AVT, BAX, BC, BLL, BMY, CAT, CELG, CL, CNX, COV, CP, CY, EQT, ESI, ETN, FNFG, IVZ, JBLU, JNS, KMT, LMT, MJN, MKC, MMM, MWW, NOK, NUE, ORI, PCP, POT, RTN, SHW, T, TWC, UA, UAL, VLY, ZMH Comment! [Earnings]
- Thursday, January 5, 2012, 9:28 AM Baxter International (BAX) initiates advanced clinical testing of its BAX 855 treatment for hemophilia A. The firm says the phase I trial is the first step in assessing if the drug can be infused less frequently. Comment! [Healthcare]
- Thursday, December 22, 2011, 4:32 PM Momenta Pharmaceuticals (MNTA) gains 5.7% AH after announcing it has entered into a collaboration with Baxter (BAX) to develop a class of drugs called biosimilars. As part of the deal, Baxter will make a $33M up-front payment to Momenta related to the development of six drug compounds, and "may make additional payments over the next several years." 1 Comment [Healthcare, On the Move]
-
The Mays Report
Baxter ( BAX ) Wins Bid to Force Teva ( TEVA ) to Honor Agreement on Hepatitis-Case Costs http://bloom.bg/qtZcdv - View all 0 replies
-
Linus Wilson
Find how much paper these firms rolled onto the Fed: BAX, GPW, ZION, KB See pages 29-30 of http://bit.ly/nNlLv2 - View all 0 replies
-
Chuck Carnevale
$BAX - Baxter International - Review the fundamentals by F.A.S.T. Graphs(tm): http://bit.ly/qAeajv - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
David Penn
HAL, MON, BAX among OEX NDX stocks pulling back again on Tuesday - more at TradingMarkets.com after the close for 7 Stocks You Need to Know - View all 0 replies
-
Justin M. Hall
RDNT, PFE, NLC, AMGN, BAX, HBIO => Notable Developments and Results 12/2/10 => Rx Investors.com => http://bit.ly/haFLnm - View all 0 replies
-
Robert Freedland
I wrote up Baxter (BAX) as an interesting company that appears to be executing well with increasing dividends, earnings, & expectations. - View all 0 replies
-
- View all 0 replies
LATEST REPLIES